Investigation of Leptin G19A polymorphism with bladder cancer risk: A case‐control study

Background A host of studies show Leptin (LEP) G19A polymorphism is correlated with the risk of various cancers, but the connection of this polymorphism with bladder cancer (BC) risk has not been reported. Materials and methods This association was in explored in a case‐control study involving 355 B...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical laboratory analysis 2020-08, Vol.34 (8), p.e23351-n/a
Main Authors: Mao, Fei, Niu, Xiao‐Bing, Gu, Shuo, Ji, Lu, Wei, Bing‐Jian, Wang, Heng‐Bing
Format: Article
Language:English
Subjects:
Age
Alleles
Bladder cancer
Deoxyribonucleic acid
DNA
Females
G19A polymorphism
Gene polymorphism
Genetic testing
Genotype & phenotype
Histology
Leptin
Males
Metastases
Metastasis
Polymerase chain reaction
Polymorphism
Restriction fragment length polymorphism
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background A host of studies show Leptin (LEP) G19A polymorphism is correlated with the risk of various cancers, but the connection of this polymorphism with bladder cancer (BC) risk has not been reported. Materials and methods This association was in explored in a case‐control study involving 355 BC cases and 435 controls (all Chinese Han). Polymerase chain reaction‐restriction fragment length polymorphism was conducted to genotype LEP G19A polymorphism. Analyses of allele and genotype distribution were evaluated using chi‐square test. Continuous data were assessed by an independent samples t test or one‐way ANOVA test. Odds ratio (OR) and 95% confidence interval (CI) were determined by logistic regression. Results LEP G19A polymorphism was significantly associated with a lower risk of BC (AA vs GG: adjusted OR, 0.40, 95% CI, 0.20‐0.83, P = .013; AA + GA vs GG: adjusted OR, 0.70, 95% CI, 0.52‐0.93, P = .015; AA vs GA + GG: adjusted OR, 0.45, 95% CI, 0.22‐0.91, P = .026). In addition, A allele was associated with decreased risk for BC (A vs G: OR, 0.70, 95% CI, 0.55‐0.89, P = .003). Stratified analyses by females, non‐drinkers, and non‐smokers all returned considerable relations. Furthermore, LEP G19A polymorphism was correlated with tumor size, tumor node metastasis, and distant metastasis in BC patients. Conclusions LEP G19A polymorphism is associated with a less risk of BC.
ISSN:0887-8013
1098-2825
DOI:10.1002/jcla.23351